Navigation Links
AMT Appoints New Chief Executive Officer
Date:9/23/2009

AMSTERDAM, September 24 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in human gene therapy, announced today the appointment of Jorn Aldag as its new Chief Executive Officer, starting October 5. Mr. Aldag has a strong record of accomplishments in the life sciences sector and more than twenty five years of experience in corporate management and finance. As former President and CEO of Evotec AG, he was instrumental in transforming the company from a technology provider to one of the leading drug discovery and development companies in Europe.

Prof. Sander van Deventer will step down as interim-CEO of AMT. He will continue to contribute to AMT as Scientific Advisor.

Ferdinand Verdonck, Chairman, voiced the satisfaction of the members of the Supervisory Board that Mr. Aldag - who was their choice amongst a field of strong candidates - is set to take on the responsibilities as AMT's CEO. They are confident that AMT will greatly benefit from Mr. Aldag's acumen and proven management skills and that the company's scientists and staff will maintain their enthusiastic commitment to develop novel therapeutic cures under his focused guidance. The Supervisory Board looks forward to Mr. van Deventer's continuing excellent contributions as Scientific Advisor to the company.

Jorn Aldag: Since its inception AMT has developed a unique and powerful gene therapy platform. The company's scientists have used this platform and excellent knowledge of gene therapy to develop a rich portfolio of potential cures. AMT's lead product Glybera is approaching registration. In addition, the company has 8 potential products under development for important orphan and non-orphan diseases. I am proud to work with the AMT team to drive its development to become a successful and profitable biopharmaceutical company.

From 2001 to 2008, Mr. Aldag was President and CEO of Evotec AG,
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer
2. The Childrens Center of Wayne County Appoints Ballantyne as Chief Development Officer
3. GENova appoints Dr. Wang Chong to Scientific Advisory Board
4. InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
5. Delcath Systems, Inc. Appoints David McDonald Chief Financial Officer
6. GENova appoints Dr. Philip Gould to Scientific Advisory Board
7. GENova appoints Director of Asian business development
8. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
9. Allscripts to Announce Fiscal First Quarter Results on September 29, 2009; Company Appoints Vice President of Investor Relations
10. KV Pharmaceutical Appoints Interim Chief Financial Officer
11. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... September 02, 2014 West Hollywood ... complimentary consultations for Invisalign. This special offer includes a ... smiles to determine their candidacy for the procedure and ... Qualified patients may also be eligible for the Summer ... remainder of the month of August, patients who choose ...
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 (HealthDay ... boost their heart health, cutting down on carbohydrates may work ... In a small clinical trial of obese adults, researchers found ... weight over a year than those who followed a low-fat ... and triglyceride levels, the research team reports in the Sept. ...
(Date:9/2/2014)... New York (PRWEB) September 02, 2014 ... announces that Class Counsel has filed an ... service awards in the class action litigation brought ... Waichman LLP, the Court-Appointed Class Counsel in this ... & Bernstein, LLP; Audet & Partners, LLP; Levin ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 A little ... everyone. But sometimes the onset of irritability, sadness, or ... reports the September 2014 Harvard Health Letter. ... to everyday stresses. If they occur for long periods, ... an indication to seek help," says Dr. Nancy Donovan, ...
Breaking Medicine News(10 mins):Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2
... CHICAGO, Oct. 20 A Chicago company that has been revolutionizing ... joined up with Harvard Common Press, the publisher of The ... guide for new moms. This package of three great resources ... download at www.thebabycd.com. , Moms can now get The Baby ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ... Phase 2 clinical data from its ZFP Therapeutic(TM) program ... (DN) at the Society for Neuroscience Annual Meeting held ... 2 clinical trial demonstrated a direct neuroregenerative effect of ...
... today,s challenging times, Ankhasha,s Temple of the Western Gate is ... and development. Ankhasha Amenti has opened the Temple in response ... and spiritual renewal in this stressful world. , The ... 34 million Americans claim no religion - up from 14 ...
... , WASHINGTON, Oct. 20 In testimony to a ... offered recommendations on ways to better meet the needs ... with special requirements. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , ... testified Tuesday as to how the Red Cross is ...
... , CHICAGO, Oct. 20 After a decade marked by ... is on the rise and is expected to continue increasing ... released today by Aon Corporation in ... Management . , (Logo: http://www.newscom.com/cgi-bin/prnh/20041215/CGW049LOGO ) ...
... liver disease who drink three or more cups of coffee ... progression than non-coffee drinkers according to a new study led ... (NCI). The study found that patients with hepatitis C-related ... disease treatment benefited from increased coffee intake. An effect ...
Cached Medicine News:Health News:New Moms to Receive FREE STIMULUS PACKAGE Worth More Than $50 2Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 2Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 3Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 4Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 5Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 6Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 7Health News:Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting 8Health News:Recession, Decline of Organized Religion Drive People to Find New Answers 2Health News:Red Cross Strives to Help Disaster's Vulnerable Population 2Health News:Red Cross Strives to Help Disaster's Vulnerable Population 3Health News:Frequency of Hospital Professional Liability Claims Increasing After Years of Declines, Says Aon and ASHRM Study 2Health News:Frequency of Hospital Professional Liability Claims Increasing After Years of Declines, Says Aon and ASHRM Study 3Health News:Frequency of Hospital Professional Liability Claims Increasing After Years of Declines, Says Aon and ASHRM Study 4Health News:Drinking coffee slows progression of liver disease in chronic hepatitis C sufferers 2
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
Megakwik Malaria ( P.falciparum ) Card Test...
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
The KAT-Quick Malaria test was designed for the diagnosis of Malaria, in laboratories, the home and for medical kits when travelling into malaria regions....
DiaMed OptiMAL-IT is an immuno-chromatographic test, using monoclonal antibodies against the metabolic enzyme pLDH (parasite lactate dehydrogenase) of Plasmodium spp. These Mabs are classified in t...
Medicine Products: